Zepbound (Tirzepatide) Injection Site Reactions When They Don't Go Away

Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist administered by once-weekly subcutaneous injection. The FDA has approved Zepbound for chronic weight management in adults who have obesity or are overweight with weight-related conditions. Mounjaro, which uses the same tirzepatide formulation, is indicated for type 2 diabetes treatment. Redness, itching, swelling, and lumps at the injection site are known local adverse effects associated with medications in this drug class. This article explains persistent injection site reactions that do not resolve as expected and how to manage them.

Most Zepbound injection site reactions are mild and resolve within a few days as the local tissue clears the injected volume. A reaction that lasts beyond about a week, keeps recurring in the exact same spot, or is accompanied by fever, spreading redness, or symptoms away from the injection site is outside that expected pattern and is worth a clinical look rather than continued home monitoring. The three most common explanations for a reaction that will not resolve are technique-related irritation, lipohypertrophy from repeated injection in one spot, and, less commonly, a hypersensitivity reaction. Each has a different fix, so identifying which one is happening matters more than trying a single remedy for all of them.

What counts as "not resolving"

There is no single official cutoff for how long an injection site reaction should last before it counts as abnormal, and readers should not treat the numbers below as a diagnostic rule. As a practical, clinically reasonable threshold that this article uses throughout:

• Redness, swelling, or itching still present after about 7 days
• A firm lump still palpable 2 to 3 weeks after the injection that caused it
• The same anatomical spot reacting every week while other sites do not
• Symptoms that get worse over days instead of peaking early and fading

Ordinary post-injection erythema typically peaks within the first hour and fades within a day or two. When a reaction departs from that pattern, it is reasonable to think about mechanism rather than simply waiting it out.

What is actually happening under the skin

Tirzepatide is injected into subcutaneous fat, where immune cells naturally sample anything foreign, including the injected fluid volume and any excipients in the formulation. A brief, mild local response is expected and is not itself a sign of a problem. The FDA-approved label for Zepbound lists injection site reactions among the drug's recognized adverse reactions and instructs prescribers to evaluate suspected hypersensitivity reactions (see the Zepbound prescribing information). We have not independently reproduced the label's exact incidence tables here; readers who want the precise trial-reported percentages by dose arm should consult that document directly rather than rely on a secondhand number.

Tirzepatide also differs pharmacologically from single-target GLP-1 drugs (such as semaglutide) because it activates the GIP receptor as well, and GIP receptors are present on fat cells near the injection depot. Whether this GIP activity meaningfully changes the local reaction profile compared to GLP-1-only drugs is a plausible hypothesis, not an established, quantified difference, and a head-to-head trial designed specifically to compare injection-site tolerability between the two drug classes does not appear to exist in the material reviewed for this page. Any specific numeric comparison between Zepbound and semaglutide-based products on this endpoint should be treated as unverified until checked against the original trial publications and labels.

The three most likely causes of a reaction that won't quit

Injection technique. Injecting the drug cold (straight from the refrigerator), too shallowly, or with air still in the needle can prolong local irritation. Repeated injection at exactly the same small spot is the single most correctable habit associated with persistent local symptoms.

Lipohypertrophy. This is a buildup of thickened, less vascular fat tissue from injecting the same 1 to 2 centimeter area repeatedly over weeks or months. It typically feels like a firm, rubbery, non-tender lump rather than an inflamed or warm one. It is well documented with repeated subcutaneous insulin injection in patients who do not rotate sites; it is reasonable to expect the same mechanism applies to any weekly subcutaneous peptide, including tirzepatide, though we did not locate a study measuring lipohypertrophy rates specifically in tirzepatide users.

Hypersensitivity. Rare but real. An immediate (Type I, IgE-mediated) reaction appears within minutes to about two hours of injection and can include hives away from the injection site, facial or throat swelling, or dizziness, this is a medical emergency. A delayed local (Type IV) reaction instead shows up as an itchy, firm plaque 1 to 3 days after injection that can take 1 to 2 weeks to fade, and is thought to reflect a T-cell response to the drug or a formulation component rather than infection.

An infected injection site is a fourth possibility that needs to be ruled out whenever a lump is warm, increasingly tender, fluctuant (feels like it contains fluid), or associated with fever or spreading red streaking. That picture requires same-day medical evaluation, not home monitoring.

Decision framework: what to do with a reaction that hasn't resolved

Use this in order. Stop and act at the first step that applies.

This framework is a triage aid, not a diagnosis. Any uncertainty about which row applies is itself a reason to call your prescribing clinician rather than guess.

Reducing the chance of a persistent reaction

Practices consistent with the FDA label and general subcutaneous injection technique:

• Let the pen warm to room temperature for at least 30 minutes before injecting; injecting cold solution is a plausible contributor to increased local irritation, though we did not find a tirzepatide-specific trial quantifying this effect.
• Rotate systematically among the abdomen, thigh, and upper arm, and avoid returning to the same small area for at least several weeks. A simple written or app-based log makes this easier than relying on memory.
• Use a new needle each time; a needle used more than once causes more tissue trauma on the way in.
• Avoid injecting into bruised, scarred, or already-reactive skin.
• Apply gentle pressure, not rubbing, for about 10 seconds after withdrawing the needle.

None of these steps will fix a true hypersensitivity reaction, and none of them substitute for the red-flag checklist above.

What is established, what is plausible, and what is not established

Established: Injection site reactions are a recognized adverse reaction of Zepbound listed on the FDA label. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide and warrant discontinuation and prompt medical evaluation when suspected, per the FDA label. Lipohypertrophy from repeated same-site subcutaneous injection is a well-established phenomenon in insulin therapy.

Plausible but not confirmed by the sources reviewed for this page: That tirzepatide's dual GIP/GLP-1 activity produces a meaningfully different local reaction profile than GLP-1-only drugs; that lipohypertrophy rates and timelines documented for insulin transfer directly, at the same frequency, to weekly tirzepatide; specific day-by-day resolution timelines for delayed hypersensitivity reactions to tirzepatide.

Not established from the material available here: Precise incidence percentages of injection site reactions by dose arm across the SURMOUNT and SURPASS trial programs. These numbers exist in the published trial reports and the FDA label, but this draft does not reproduce them because the citation chain available for this article could not be independently verified against the primary papers. An editor with direct access to the trial publications and current label should confirm and reinsert exact figures before publication.

When to seek urgent care instead of waiting

Go to urgent or emergency care, do not wait for a scheduled appointment, if you notice any of the following after a Zepbound injection:

• Hives, swelling of the face or throat, difficulty breathing, or dizziness within minutes to a couple of hours of injecting
• Fever with a worsening injection site
• Red streaking spreading away from the injection site
• A lump that becomes increasingly painful, warm, and fluid-feeling

For anything less urgent, but still not resolving after a week or two of corrected technique, contact your prescribing clinician rather than continuing to self-manage.

Talking to your prescriber

Bring specifics rather than a general description. Useful details include: the exact site used, how long after injection symptoms started, the peak size of any redness or swelling (in centimeters if you can estimate it), how many days each reaction lasted, whether it is getting worse or staying the same from dose to dose, and any symptoms away from the injection site. A clinician with that timeline can usually tell a technique problem apart from a hypersensitivity pattern in one visit. Patients and providers can also report persistent or serious reactions through the FDA's MedWatch program, which feeds the FDA's adverse event reporting database used for post-marketing safety surveillance.